Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Joseph Klein III sold 6,000 shares of the company's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $42.71, for a total transaction of $256,260.00. Following the completion of the transaction, the director now owns 16,346 shares in the company, valued at $698,137.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Ionis Pharmaceuticals Stock Down 3.2 %
Shares of Ionis Pharmaceuticals stock opened at $40.93 on Wednesday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90. Ionis Pharmaceuticals, Inc. has a 52-week low of $34.79 and a 52-week high of $54.44. The company's 50 day moving average price is $42.86 and its 200-day moving average price is $46.92. The stock has a market capitalization of $5.97 billion, a price-to-earnings ratio of -15.99 and a beta of 0.41.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The business had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. During the same quarter last year, the firm earned ($0.37) EPS. The company's revenue was up 113.8% on a year-over-year basis. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current year.
Institutional Trading of Ionis Pharmaceuticals
He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”
From InvestorPlace | Ad
For over four decades, Louis Navellier has found the very best tech stocks...
Before the rest of the market.
Click for his six specific AI stock in the crosshairs
Several large investors have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC purchased a new stake in Ionis Pharmaceuticals in the 1st quarter worth approximately $1,976,000. SG Americas Securities LLC lifted its stake in Ionis Pharmaceuticals by 23.7% in the first quarter. SG Americas Securities LLC now owns 7,582 shares of the company's stock worth $329,000 after acquiring an additional 1,453 shares during the period. Grandfield & Dodd LLC boosted its holdings in Ionis Pharmaceuticals by 2.0% in the first quarter. Grandfield & Dodd LLC now owns 33,774 shares of the company's stock valued at $1,464,000 after acquiring an additional 670 shares in the last quarter. Nicollet Investment Management Inc. increased its position in Ionis Pharmaceuticals by 109.9% during the 1st quarter. Nicollet Investment Management Inc. now owns 20,521 shares of the company's stock valued at $890,000 after purchasing an additional 10,745 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Ionis Pharmaceuticals in the 1st quarter worth $613,000. 93.86% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
IONS has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their price target on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a "neutral" rating in a report on Thursday, February 1st. Oppenheimer raised their price target on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an "outperform" rating in a research report on Tuesday, April 9th. Royal Bank of Canada increased their price objective on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an "outperform" rating in a research report on Friday, January 26th. StockNews.com upgraded Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 24th. Finally, Wolfe Research raised Ionis Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $58.00 target price for the company in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $57.67.
Get Our Latest Report on IONS
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
